Best Stocks Under $10 Right Now

Show:
Clean Energy Fuels stock logo

#1 - Clean Energy Fuels

NASDAQ:CLNE
Stock Price:
$2.33 (+$0.01)
P/E Ratio:
-5.30
Market Cap:
$520.20 million
Average Trading Volume:
1.62 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.60 (140.3% Upside)
Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
Zura Bio stock logo

#2 - Zura Bio

NASDAQ:ZURA
Stock Price:
$4.36 (+$0.21)
Market Cap:
$187.87 million
Average Trading Volume:
284,363 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$16.40 (276.1% Upside)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Ardelyx stock logo

#3 - Ardelyx

NASDAQ:ARDX
Stock Price:
$6.79 (+$0.18)
P/E Ratio:
-22.63
Market Cap:
$1.59 billion
Average Trading Volume:
6.04 million shares
Consensus Rating:
Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$12.69 (86.9% Upside)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Innergex Renewable Energy stock logo

#4 - Innergex Renewable Energy

OTCMKTS:INGXF
Stock Price:
$6.09 (+$0.08)
P/E Ratio:
-16.03
Market Cap:
$1.24 billion
Average Trading Volume:
41,147 shares
Dividend Yield:
9.38%
<
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.60 (320.4% Upside)
Innergex Renewable Energy Inc. operates as an independent renewable power producer in Canada, the United States, France, and Chile. It acquires, owns, develops, and operates renewable power-generating and energy storage facilities primarily in hydroelectric, wind, and solar power sectors. The company operates through three segments: Hydroelectric Power Generation, Wind Power Generation, and Solar Power Generation. As of February 21, 2024, it owned and operated 87 facilities with a net installed capacity of 3,600 megawatts, including 41 hydroelectric facilities, 35 wind facilities, 9 solar facilities, and 2 battery energy storage facilities. The company is headquartered in Longueuil, Canada.
Integra Resources stock logo

#5 - Integra Resources

NYSEAMERICAN:ITRG
Stock Price:
$0.76
P/E Ratio:
-1.40
Market Cap:
$67 million
Average Trading Volume:
134,602 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.75 (395.1% Upside)
Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
BlackSky Technology stock logo

#6 - BlackSky Technology

NYSE:BKSY
Stock Price:
$1.28 (+$0.05)
P/E Ratio:
-3.12
Market Cap:
$187.93 million
Average Trading Volume:
594,239 shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.63 (105.1% Upside)
BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems for government and commercial customers in North America, the Middle East, the Asia Pacific, and internationally. The company's Spectra software platform processes a range of observations from its satellite constellation and various external data sources, including imaging, radar and radio frequency satellites, environmental sensors, asset tracking sensors, Internet-of-Things (IoT) connected devices, internet-enabled narrative sources, and a variety of geotemporal data feeds. It offers a range of services related to object, change and anomaly detection, site monitoring, and enhanced analytics, which helps to detect key pattern of life changes in critical locations, including strategic locations and infrastructure comprising ports, airports, and construction sites; retail activity; commodities stockpiles; and other sites that contain critical commodities and supply chain inventory. In addition, the company develops and delivers satellites and payload systems; and provides professional and engineering services. Its products and services are used in national security, supply chain intelligence, crisis management, critical infrastructure monitoring, economic intelligence, and other applications. BlackSky Technology Inc. was incorporated in 2018 and is headquartered in Herndon, Virginia.
Rani Therapeutics stock logo

#7 - Rani Therapeutics

NASDAQ:RANI
Stock Price:
$6.37
P/E Ratio:
-4.79
Market Cap:
$319.52 million
Average Trading Volume:
121,820 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$11.50 (80.5% Upside)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Kingfisher stock logo

#8 - Kingfisher

OTCMKTS:KGFHY
Stock Price:
$6.10 (-$0.07)
Market Cap:
$5.71 billion
Average Trading Volume:
458,609 shares
Dividend Yield:
2.67%
<
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kingfisher plc, together with its subsidiaries, supplies home improvement products and services primarily in the United Kingdom, Ireland, France, and internationally. The company also offers property investment, finance, digital, sourcing, and IT services. It also operates retail stores under the B&Q, Castorama, Brico Dépôt, Screwfix, TradePoint, and Koçtas brands. The company sells its products through stores and e-commerce channels. Kingfisher plc was incorporated in 1982 and is headquartered in London, the United Kingdom.
Uranium Energy stock logo

#9 - Uranium Energy

NYSEAMERICAN:UEC
Stock Price:
$7.12 (+$0.28)
P/E Ratio:
-712.00
Market Cap:
$2.88 billion
Average Trading Volume:
7.78 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (23.6% Upside)
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Goliad, Burke Hollow, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Dalton Pass and C de Baca project located in New Mexico; Roughrider, Shea Creek, Christie Lake, Horseshoe-Raven, Hidden Bay, Diabase, West Bear, JCU, and other project located in Canada; and Yuty, Oviedo, and Alto Paraná titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
Taboola.com stock logo

#10 - Taboola.com

NASDAQ:TBLA
Stock Price:
$4.40 (+$0.12)
P/E Ratio:
-18.33
Market Cap:
$1.30 billion
Average Trading Volume:
1.33 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.79 (31.6% Upside)
Taboola.com Ltd., together with its subsidiaries, operates an artificial intelligence-based algorithmic engine platform in Israel, the United States, the United Kingdom, Germany, and internationally. It offers Taboola, a platform that partners with websites, devices, and mobile apps to recommend editorial content and advertisements on the open web to users. The company was incorporated in 2006 and is headquartered in New York, New York.
Mama's Creations stock logo

#11 - Mama's Creations

NASDAQ:MAMA
Stock Price:
$6.38 (+$0.38)
P/E Ratio:
35.44
Market Cap:
$237.72 million
Average Trading Volume:
289,733 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.88 (23.4% Upside)
Mama's Creations, Inc., together with its subsidiaries, manufactures and markets prepared refrigerated foods primarily in the United States. The company offers beef and turkey meatballs, meat loaf, chicken, sausage-related products, and pasta entrees; and hot bars, salad bars, prepared foods, sandwich, and cold deli and foods-to-go sections. It sells its products directly to supermarkets, club chains, and mass-market retailers; and food retailers and distributors, as well as through website. The company was formerly known as MamaMancini's Holdings, Inc. and changed its name to Mama's Creations, Inc. in August 2023. Mama's Creations, Inc. was founded in 2009 and is headquartered in East Rutherford, New Jersey.
St. James's Place stock logo

#12 - St. James's Place

OTCMKTS:STJPF
Stock Price:
$5.35
P/E Ratio:
18.84
Average Trading Volume:
3,067 shares
Dividend Yield:
2.36%
<
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1,767.00 (32,928.0% Upside)
St. James's Place plc is a publicly owned investment manager. The firm launches and manages equity, fixed income, and balanced mutual funds for its clients. It invests in public equity and fixed income market across the globe. The firm was formerly known as St. James's Place Capital plc. St. James's Place plc was founded in 1991 and is based in Cirencester, United Kingdom.
Actinium Pharmaceuticals stock logo

#13 - Actinium Pharmaceuticals

NYSEAMERICAN:ATNM
Stock Price:
$8.75 (+$0.97)
P/E Ratio:
-5.12
Market Cap:
$260.58 million
Average Trading Volume:
324,886 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.72 (193.9% Upside)
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
D-Wave Quantum stock logo

#14 - D-Wave Quantum

NYSE:QBTS
Stock Price:
$1.45 (+$0.04)
P/E Ratio:
-2.34
Market Cap:
$234.44 million
Average Trading Volume:
3.98 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.80 (93.1% Upside)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community. It also provides D-Wave Launch, a quantum professional service that guides enterprises from problem discovery through production implementation. The company's quantum solutions are used in logistics, financial services, drug discovery, materials sciences, scheduling, fault detection, mobility, and supply chain management. It serves financial services, manufacturing/logistics, mobility, and life sciences/pharmaceuticals industries. D-Wave Quantum Inc. was founded in 1999 and is headquartered in Burnaby, Canada.
Ocular Therapeutix stock logo

#15 - Ocular Therapeutix

NASDAQ:OCUL
Stock Price:
$5.87 (+$0.85)
P/E Ratio:
-4.70
Market Cap:
$908.27 million
Average Trading Volume:
2.25 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.60 (199.8% Upside)
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Man Group stock logo

#16 - Man Group

OTCMKTS:MNGPF
Stock Price:
$3.55
P/E Ratio:
121.21
Average Trading Volume:
1,233 shares
Dividend Yield:
3.50%
<
Consensus Rating:
Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$128.50 (3,519.7% Upside)
Man Group Limited is a publicly owned investment manager. The firm provides long-only and alternative investment management services worldwide. It offers a range of liquid investment products and solutions, which include quantitative, multi-manager and discretionary investment styles, and span across various asset classes, like equity, real estate, currency, credit, volatility, and commodities. The firm distributes its products and solutions directly to institutions and to private investors through a global network of intermediaries. Man Group Limited was founded in 1783 and is based in St. Helier, Jersey with an additional office in London, United Kingdom.
biote stock logo

#17 - biote

NASDAQ:BTMD
Stock Price:
$5.78 (+$0.13)
P/E Ratio:
-26.27
Market Cap:
$430.80 million
Average Trading Volume:
105,177 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.11 (40.3% Upside)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Pyxis Oncology stock logo

#18 - Pyxis Oncology

NASDAQ:PYXS
Stock Price:
$4.41 (+$0.01)
P/E Ratio:
-2.40
Market Cap:
$259.66 million
Average Trading Volume:
761,988 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.50 (92.7% Upside)
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
indie Semiconductor stock logo

#19 - indie Semiconductor

NASDAQ:INDI
Stock Price:
$5.81 (+$0.33)
P/E Ratio:
-6.84
Market Cap:
$1.06 billion
Average Trading Volume:
2.69 million shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$13.50 (132.4% Upside)
indie Semiconductor, Inc. provides automotive semiconductors and software solutions for advanced driver assistance systems, autonomous vehicle, in-cabin, connected car, and electrification applications in the United States, South America, rest of North America, Greater China, South Korea, rest of the Asia Pacific, and Europe. It offers ultrasonic sensors for parking assist and systems; radar sensors for audio assistance and reverse information; front cameras for vehicle detection, collision avoidance, and sign reading; and side/inside cameras for blind spot and lane change assist, and driver behavior monitoring. The company also provides LiDAR for distance, speed, and obstacle detection, collision avoidance, and emergency brake system; and long range RADAR for audio assistance, obstacle detection, and ACC stop and go. In addition, it designs and manufactures photonic components on various technology platforms, including fiber Bragg gratings, low-noise lasers, athermal and tunable packaging, photonic integration, and low-noise and high-speed electronics. The company was founded in 2007 and is headquartered in Aliso Viejo, California.
Applied Digital stock logo

#20 - Applied Digital

OTCMKTS:APLD
Stock Price:
$2.96 (-$0.04)
P/E Ratio:
-6.04
Market Cap:
$363.31 million
Average Trading Volume:
3.64 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$14.70 (396.6% Upside)
Applied Digital Corporation designs, develops, and operates datacenters in North America. Its datacenters provide digital infrastructure solutions to the high-performance computing industry. The company also provides artificial intelligence cloud services, high performance computing datacenter hosting, and crypto datacenter hosting services. The company was formerly known as Applied Blockchain, Inc. and changed its name to Applied Digital Corporation in November 2022. Applied Digital Corporation is based in Dallas, Texas.
Cantaloupe stock logo

#21 - Cantaloupe

NASDAQ:CTLP
Stock Price:
$5.94 (+$0.06)
P/E Ratio:
31.26
Market Cap:
$432.43 million
Average Trading Volume:
300,048 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$9.70 (63.3% Upside)
Cantaloupe, Inc., a digital payments and software services company, provides technology solutions for the unattended retail market. The company offers integrated solutions for payments processing, logistics, and back-office management. It also provides ePort, an integrated payment device that is deployed in self-service, unattended market applications, such as vending, micro-markets, amusement, arcade, commercial laundry, air/vacuum, car wash, and others, which facilitates digital payments; and integrated software services for payment or asset tracking devices. In addition, the company offers G11 cashless kit, a 4G LTE digital payment device or payment and consumer engagement applications; G11 chip kit, a digital reader that accepts contact EMV (chip cards) and contactless EMV (tap) payment methods; Engage series comprising Engage and Engage Combo, which are digital touchscreen devices that provides networking, security, and interactivity payment methods. Further, it provides self-checkout kiosks,?smart store?concepts, and the Cantaloupe Go management platform comprising Go Mini, Go MiniX, Go Plus 100, Go Plus 200, Go Plus 300, Go Max, Cooler Café, Smart Market, and Go Portal, a robust cloud-based platform, as well as Go consumer mobile app, loyalty programs, campus card integrations, digital ad-management, and data warehouse services. The company was formerly known as USA Technologies, Inc and changed its name to Cantaloupe, Inc. Cantaloupe, Inc. was incorporated in 1992 and is headquartered in Malvern, Pennsylvania.
Vor Biopharma stock logo

#22 - Vor Biopharma

NYSE:VOR
Stock Price:
$1.76 (-$0.01)
P/E Ratio:
-1.00
Market Cap:
$120.07 million
Average Trading Volume:
286,373 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$13.50 (667.0% Upside)
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Amneal Pharmaceuticals stock logo

#23 - Amneal Pharmaceuticals

NASDAQ:AMRX
Stock Price:
$6.21 (+$0.09)
P/E Ratio:
-20.03
Market Cap:
$1.91 billion
Average Trading Volume:
1.54 million shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.31 (17.8% Upside)
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
easyJet stock logo

#24 - easyJet

OTCMKTS:ESYJY
Stock Price:
$6.85 (+$0.02)
P/E Ratio:
1.51
Average Trading Volume:
12,688 shares
Dividend Yield:
2.60%
<
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
easyJet plc operates as a low-cost airline carrier in Europe. The company engages in the provision of holiday packages; aircraft trading and leasing activities; development of building projects; financing and insurance business; and tour operator activities. easyJet plc was founded in 1995 and is headquartered in Luton, the United Kingdom.
Relay Therapeutics stock logo

#25 - Relay Therapeutics

NASDAQ:RLAY
Stock Price:
$7.08 (+$0.42)
P/E Ratio:
-2.53
Market Cap:
$936.97 million
Average Trading Volume:
1.14 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$26.00 (267.2% Upside)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Ideas from MarketBeat